NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Pre-Mkt 02-10 05:32:09 EST

10.03

-0.11

-1.08%

High10.20	Low9.82	Vol1.21M
Open10.12	D1 Closing10.14	Amplitude3.75%
Mkt Cap1.12B	Tradable Cap944.30M	Total Shares111.98M
T/O12.13M	T/O Rate1.29%	Tradable Shares94.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":10.03,"timestamp":1770670800000,"preClose":10.14,"halted":0,"volume":1214984,"delay":0,"changeRate":-0.010848126232741735,"floatShares":94147892,"shares":111981981,"eps":-1.60741,"marketStatus":"Pre-Mkt","change":-0.11,"latestTime":"02-10 05:32:09 EST","open":10.12,"high":10.2,"low":9.82,"amount":12130928.774039999,"amplitude":0.037475,"askPrice":11.09,"askSize":100,"bidPrice":8.8,"bidSize":36,"shortable":3,"etf":0,"ttmEps":-1.60741,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":10.03,"postHourTrading":{"tag":"盘后","latestPrice":10.06,"preClose":10.03,"latestTime":"19:43 EST","volume":22642,"amount":227112.111,"timestamp":1770684229120,"change":0.03,"changeRate":0.002991,"amplitude":0.00349},"volumeRatio":0.5363173748147136,"impliedVol":1.1087,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"2609518060","title":"Wedbush Reaffirms Their Hold Rating on NovoCure (NVCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609518060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609518060?lang=en_us&edition=fundamental","pubTime":"2026-02-07 01:15","pubTimestamp":1770398138,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Hold rating on NovoCure today and set a price target of $18.00. In addition to Wedbush, NovoCure also received a Hold ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-hold-rating-on-novocure-nvcr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-hold-rating-on-novocure-nvcr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"2609307905","title":"Maintaining Buy on NovoCure: Viewing CMS Billing Revocation as a Temporary Administrative Setback with Limited Long-Term Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2609307905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609307905?lang=en_us&edition=fundamental","pubTime":"2026-02-06 00:15","pubTimestamp":1770308137,"startTime":"0","endTime":"0","summary":"NovoCure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-novocure-viewing-cms-billing-revocation-as-a-temporary-administrative-setback-with-limited-long-term-impact-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-novocure-viewing-cms-billing-revocation-as-a-temporary-administrative-setback-with-limited-long-term-impact-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","CMS","BK4581","LU1894683264.USD","BK4082","LU2346227817.USD","LU1894683348.USD","LU0545039389.USD","LU1003077747.HKD","XBI","BK4548","XLV","BK4208","LU0738911758.USD","BK4588","LU2500361329.USD","LABU","LU0949170772.SGD","LU0661504455.SGD","NVCR","BK4585","LU2637428348.USD","LU0553294199.USD"],"gpt_icon":0},{"id":"2609089373","title":"Novocure Inc. Faces CMS Billing Privilege Revocation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609089373","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609089373?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:03","pubTimestamp":1770296599,"startTime":"0","endTime":"0","summary":"Novocure Ltd.'s U.S. subsidiary, Novocure Inc., recently received notice from the Centers for Medicare & Medicaid Services  that its billing privileges for its products were revoked retroactive to December 17, 2025. The revocation was due to an administrative process issue related to the triannual re-validation process. Novocure Inc. has filed a Corrective Action Plan with CMS and expects billing privileges to be reinstated, but the timing remains uncertain. During this period, Novocure Inc. continues to provide services to existing and new patients but cannot bill CMS payors for services rendered since the revocation date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2C9L4j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4534","NVCR","BK4588","BK4585","BK4082"],"gpt_icon":0},{"id":"2603985643","title":"Novocure Price Target Maintained With a $18.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603985643?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:13","pubTimestamp":1768486380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 09:13 ET (14:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","NVCR","BK4082","BK4534","BK4548"],"gpt_icon":0},{"id":"2603674681","title":"Novocure Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603674681","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603674681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:53","pubTimestamp":1768308780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:53 ET (12:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","NVCR","BK4082","BK4585","BK4588","BK4534"],"gpt_icon":0},{"id":"2603681213","title":"NovoCure (NVCR) Gets a Hold from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681213?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:46","pubTimestamp":1768308398,"startTime":"0","endTime":"0","summary":"In a report released today, Larry Biegelsen from Wells Fargo maintained a Hold rating on NovoCure, with a price target of $13.50. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novocure-nvcr-gets-a-hold-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novocure-nvcr-gets-a-hold-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4506","LU0208291251.USD","BK4531","IE00B7SZLL34.SGD","LU0070302665.USD","LU0211328371.USD","LU0251142724.SGD","LU0980610538.SGD","LU0251131958.USD","LU0106831901.USD","LU0128525689.USD","LU1035773651.USD","LU0211327993.USD","LU0683600562.USD","NVCR","BK4548","LU0314106906.USD","LU0162691827.USD","LU1280957306.USD","LU0029864427.USD","LU0942090050.USD","LU1668664300.SGD","LU1363072403.SGD","BK4588","LU0130102774.USD","LU0154236417.USD","BK4204","LU0787776722.HKD","LU0971096721.USD","LU0128525929.USD","BK4510","LU1267930573.SGD","BK4501","LU1791807156.HKD","BK4585","LU0320765489.SGD","LU0708994859.HKD","LU1894683348.USD","LU2361045086.USD","BK4504","GOTU","LU0048573561.USD","LU0477156953.USD","LU1267930490.SGD","LU2461242641.AUD","BK4559","LU2361044949.HKD","IE00B19Z3581.USD","LU0648001328.SGD","LU1267930227.SGD"],"gpt_icon":0},{"id":"2603688702","title":"Novocure Limited : H.c. Wainwright Cuts Target Price to $39 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2603688702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603688702?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:05","pubTimestamp":1768302304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nAZN4RXTED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","NVCR","BK4082","BK4534","BK4548","BK4585"],"gpt_icon":0},{"id":"2603542868","title":"Novocure Names Frank Leonard as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603542868","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603542868?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:27","pubTimestamp":1768235275,"startTime":"0","endTime":"0","summary":"Novocure Ltd. has announced the appointment of Frank Leonard as Chief Executive Officer. Leonard previously served as the company's President.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4dcV24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4585","BK4548","BK4534","BK4588","BK4082"],"gpt_icon":0},{"id":"2602176935","title":"NovoCure Reports Rise in Q4 Preliminary Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2602176935","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602176935?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:45","pubTimestamp":1768221902,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) said Monday its total preliminary net revenues for Q4 were $174.4 million, up 8% compared with a year earlier.Analysts polled by FactSet expect $168.3 million.As of Dec. 31, 2025, cash, cash equivalents, and short-term investments were $448.3 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"gpt_icon":0},{"id":"2602751262","title":"Novocure reports preliminary Q4 revenue $174.4M, consensus $168.93M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602751262","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602751262?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:16","pubTimestamp":1768220194,"startTime":"0","endTime":"0","summary":"Reports Preliminary FY25 revenue $655.4M, consensus $651.21M. “Novocure (NVCR) exits 2025 having achieved record annual revenue, providing the fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-reports-preliminary-q4-revenue-174-4m-consensus-168-93m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-reports-preliminary-q4-revenue-174-4m-consensus-168-93m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4585","BK4534","NVCR","BK4548","BK4588"],"gpt_icon":0},{"id":"2602514191","title":"Novocure Reports Record 2025 Revenue with 8% Annual Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514191","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514191?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:02","pubTimestamp":1768219326,"startTime":"0","endTime":"0","summary":"Novocure Ltd. reported preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2025. The company recorded total preliminary net revenues of $655.4 million for the year, marking an 8% increase compared to the prior year. For the fourth quarter, total preliminary net revenues were $174.4 million, also reflecting an 8% increase from the same period in 2024. In the fourth quarter, net revenue contributions by market included $101.6 million from the U.S., $21.6 million from Germany, $20.5 million from France, and $10.2 million from Japan. Other active markets contributed $15.8 million, while revenue from Greater China, through Novocure's partnership with Zai Lab, totaled $4.6 million. Recognized revenue from Optune Lua in the quarter was $3.5 million, with $2.4 million from non-small cell lung cancer  and $1.1 million from malignant pleural mesothelioma . The company stated it is positioned for multiple product launches in 2026 and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9p5hZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4588","BK4585","09688","BK1574","BK4534","BK1588","BK1161","LU2488822045.USD","BK4082","BK4548"],"gpt_icon":0},{"id":"2602974514","title":"Novocure Ltd - in Q1 2026, Intends to Stop Reporting New Prescriptions Received in Indications Which Were Commercially Available for Over a Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2602974514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602974514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA86TXNZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4548","BK4534","NVCR","BK4588","BK4082"],"gpt_icon":0},{"id":"2602951452","title":"Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2602951452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602951452?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA86TXNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCR","BK4548","BK4585","BK4082","BK4588","BK4534"],"gpt_icon":0},{"id":"2602514100","title":"Novocure Ltd  FY2025 REV View $651.2 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514100?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA86TXNZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4588","BK4548","NVCR","BK4082","BK4585"],"gpt_icon":0},{"id":"2602351497","title":"Novocure Ltd - Will Continue to Report Active Patients on Therapy Segmented by Product (Optune Gio, Optune Lua) and Material Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351497?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA86TXNZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4585","BK4588","NVCR","BK4548","BK4534"],"gpt_icon":0},{"id":"2602051457","title":"Novocure Ltd - Prelim 2025 Net Revenues of $655 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602051457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602051457?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA86TXNZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4585","BK4588","NVCR","BK4082","BK4534"],"gpt_icon":0},{"id":"2595725705","title":"It’s Earnings Warning Season. How to Profit From Others’ Misery","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595725705?lang=en_us&edition=fundamental","pubTime":"2026-01-01 23:00","pubTimestamp":1767279600,"startTime":"0","endTime":"0","summary":"January is an optimistic time of year for investors, but not necessarily for corporate America.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9c084b36ba0e1e4ad2a94bff2fcea0b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4121","BK4585","LU1974910355.USD","HOLX","LU0053666078.USD","BK4534","SLAB","ANF","BK4094","CDNA","BK4139","ORC","BK4548","BK4202","LU2468319806.SGD","AEO","ALNY","LU0114720955.EUR","BK4200","IDCC","STAA","FIVE","REGN","ILMN","LU2023250504.SGD","BK4504","LU2362540622.SGD","TMUS","LU0823434740.USD","LU0289739699.SGD","LU2089984988.USD","LU2106854487.HKD","LU0320765992.SGD","LU0823434583.USD","QDEL","HALO","BK4535","LU0889565916.HKD","GMED","PTCT","LU2362541273.HKD","IPAR","LU0823411888.USD","LU0058720904.USD","BK4588","LU1917777945.USD","PCRX","FOLD","LU1496350502.SGD","LULU","EXAS","DXCM","LU2237438978.USD","LU0823416689.USD","LU0882574055.USD","LU0109394709.USD","DHR","LU2362541513.USD"],"gpt_icon":0},{"id":"2593840994","title":"Novocure to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2593840994","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593840994?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:01","pubTimestamp":1766404880,"startTime":"0","endTime":"0","summary":"Novocure Ltd. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 12 to 15, 2026. Chief Executive Officer Frank Leonard is scheduled to present on January 14 at 9:45 a.m. PST, joined by Executive Chairman William Doyle and Chief Financial Officer Christoph Brackmann for one-on-one investor meetings during the conference. A live audio webcast of the presentation will be available on Novocure's Investor Relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9bswP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4548","BK4585","BK4534","BK4082","BK4588"],"gpt_icon":0},{"id":"2590247823","title":"Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590247823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590247823?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:28","pubTimestamp":1765301332,"startTime":"0","endTime":"0","summary":"NovoCure has announced that CEO and Director Ashley Cordova resigned effective November 30, 2025, with President Frank Leonard stepping into the Chief Executive Officer role from December 1, 2025, while Executive Chairman William F. Doyle represented the company at the Piper Sandler Healthcare Conference shortly thereafter.\nThe leadership handover to Leonard, a long-time internal executive who has overseen global operations and innovation, suggests continuity in both commercial execution and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/does-novocures-nvcr-internal-ceo-transition-reinforce-or-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/does-novocures-nvcr-internal-ceo-transition-reinforce-or-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVCR","BK4588","BK4585","BK4534","BK4082","BK4548"],"gpt_icon":0},{"id":"2588722709","title":"How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722709","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722709?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:24","pubTimestamp":1764617094,"startTime":"0","endTime":"0","summary":"On December 1, 2025, NovoCure announced that Ashley Cordova resigned from her role as Chief Executive Officer and Board Director, effective at the end of November, with Frank Leonard, formerly President and an established leader within the company, appointed as the new CEO.\nFrank Leonard’s long-standing experience in global operations, product development, and business growth at NovoCure may provide important continuity and insight as the company enters its next phase.\nWe’ll explore how...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/how-investors-are-reacting-to-novocure-nvcr-ceo-transition-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/how-investors-are-reacting-to-novocure-nvcr-ceo-transition-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","NVCR","BK4211","BK4585","ISBC","BK4082","BK4534","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.1772},{"period":"1month","weight":-0.301},{"period":"3month","weight":-0.1543},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.5492},{"period":"ytd","weight":-0.2243}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.028412},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017692},{"month":4,"riseRate":0.5,"avgChangeRate":0.079553},{"month":5,"riseRate":0.8,"avgChangeRate":0.134604},{"month":6,"riseRate":0.4,"avgChangeRate":-0.026837},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004605},{"month":8,"riseRate":0.6,"avgChangeRate":0.019977},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}